This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Calfee, J. E. Search for Related Content PubMed Articles by Calfee, J. E.

Can Quality-Adjusted Life Year Avoidance Help in Oncology Drug Reimbursement Decisions?

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

John E. Calfee, PhD

Oncologists who advise payment authorities in Canada or elsewhere have good reasons to worry about which new therapies to fund. The last 6 or so years have seen the arrival of numerous drugs costing tens of thousands of US dollars per patient annually. Most of these drugs exploit biotechnology methods to target biological processes with exceptional specificity, often leading to therapeutics that for practical purposes, are nearly unique in their clinical effects. Clinical and financial success begets ever faster development, so we can expect many more such drugs.¹ Moreover, combination therapy may become almost as common . . . [Click for More]